Adverse effects of high dose XXXX on platelet adhesion to experimental autogenous vein grafts.

@entity117 @entity1373 @entity95 @entity4341 @entity715 @entity1281
Prostacyclin (PGI2) production and platelet adhesion were studied in veins grafted into the arterial system of @entity95 . Animal groups consisted of: no treatment; low dose @entity117 ( @entity1281 ) (0.5 mg . kg-1 X 24 h-1) plus @entity4341 (2 mg . kg-1 X 6 h-1); high dose @entity1281 (40 mg . kg-1 X 24 h-1) plus @entity4341 (2 mg . kg-1 X 6 h-1); @entity4341 (2 mg . kg-1 X 6 h-1) alone. Results showed that vein grafts from animals treated with high dose @entity1281 plus @entity4341 produced significantly less PGI2 than the other three groups (p less than 0.05 compared with the @entity4341 group; p less than 0.01 compared with the other two groups). In addition, there was significantly greater platelet deposition on the vein grafts from this high dose @entity1281 group as compared to the low dose @entity1281 group (p less than 0.05). By contrast, animals treated with @entity4341 alone had significantly less platelet deposition compared to both the control and high dose @entity1281 groups (p less than 0.05). High dose @entity1281 given to prevent @entity715 following coronary artery bypass grafting may, by reducing PGI2, result in enhanced platelet deposition. This in turn is likely to @entity1373 as has been demonstrated previously with high dose @entity1281 . Clinical studies, which have shown the early anti-thrombotic benefits of high dose @entity1281 plus @entity4341 , have not measured graft intimal thickness. Since this process is an important cause of graft narrowing, @entity1281 , in high dose, may adversely affect long-term graft survival.
